Response to lamivudine treatment in children with chronic hepatitis B virus infection
- PMID: 14614664
- DOI: 10.1086/378739
Response to lamivudine treatment in children with chronic hepatitis B virus infection
Abstract
Despite the recent approval of lamivudine for the treatment of children with chronic hepatitis B virus (HBV) infection, there is insufficient information on the kinetics of HBV clearance and the factors that predict a favorable treatment response to lamivudine in this population. In a small retrospective study of 16 HBV-infected children treated with lamivudine, we examined changes in virus load and other factors associated with hepatitis B e antigen (HBeAg) clearance. High pretherapy alanine aminotransferase level, low serum HBV DNA load, and age at the start of treatment were independently associated with HBeAg clearance. HBeAg clearance was also associated with the achievement of specific levels of virus suppression, and failure to achieve those levels was associated with the development of lamivudine resistance. Additional studies are necessary to provide better indications and guidelines for the treatment of children with chronic HBV infection.
Similar articles
-
A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.Med Sci Monit. 2002 Apr;8(4):CR257-62. Med Sci Monit. 2002. PMID: 11951067 Clinical Trial.
-
Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon.Pediatr Infect Dis J. 2003 Mar;22(3):224-9. doi: 10.1097/01.inf.0000055062.64965.2e. Pediatr Infect Dis J. 2003. PMID: 12634582 Clinical Trial.
-
Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.Antivir Ther. 2007;12(3):345-53. Antivir Ther. 2007. PMID: 17591024 Clinical Trial.
-
Clinical experience with lamivudine.Semin Liver Dis. 2002;22 Suppl 1:15-21. doi: 10.1055/s-2002-35696. Semin Liver Dis. 2002. PMID: 12447725 Review.
-
Natural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impacts.J Biomed Sci. 2015 Oct 20;22:92. doi: 10.1186/s12929-015-0199-y. J Biomed Sci. 2015. PMID: 26487087 Free PMC article. Review.
Cited by
-
Lamivudine resistance in children with chronic hepatitis B.World J Hepatol. 2015 Apr 28;7(6):896-902. doi: 10.4254/wjh.v7.i6.896. World J Hepatol. 2015. PMID: 25937866 Free PMC article. Review.
-
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int. 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4. Epub 2015 Nov 13. Hepatol Int. 2016. PMID: 26563120 Free PMC article.
-
Predictive factors of lamivudine treatment success in an hepatitis B virus-infected pediatric cohort: a 10-year study.Can J Gastroenterol. 2012 Jul;26(7):429-35. doi: 10.1155/2012/928912. Can J Gastroenterol. 2012. PMID: 22803017 Free PMC article.
-
Pediatric hepatitis B treatment.Ann Transl Med. 2017 Feb;5(3):37. doi: 10.21037/atm.2016.11.52. Ann Transl Med. 2017. PMID: 28251116 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
